|
CAPRIN1 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.989000E-01 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.899200E-01 |
| Normal-vs-Stage2 |
1.990760E-01 |
| Normal-vs-Stage3 |
1.183970E-01 |
| Normal-vs-Stage4 |
1.979000E-01 |
| Stage1-vs-Stage2 |
3.679800E-01 |
| Stage1-vs-Stage3 |
1.754440E-01 |
| Stage1-vs-Stage4 |
4.160200E-01 |
| Stage2-vs-Stage3 |
9.270400E-01 |
| Stage2-vs-Stage4 |
9.178800E-01 |
| Stage3-vs-Stage4 |
8.295400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.589600E-01 |
| Normal-vs-AfricanAmerican |
6.420400E-01 |
| Normal-vs-Asian |
2.648200E-01 |
| Caucasian-vs-AfricanAmerican |
2.666000E-01 |
| Caucasian-vs-Asian |
7.283200E-01 |
| AfricanAmerican-vs-Asian |
2.119400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.740650E-01 |
| Normal-vs-Female |
3.886400E-01 |
| Male-vs-Female |
4.107800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.003200E-01 |
| Normal-vs-Age(41-60Yrs) |
1.464410E-01 |
| Normal-vs-Age(61-80Yrs) |
1.651600E-01 |
| Normal-vs-Age(81-100Yrs) |
1.139160E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.028000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.546220E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.171600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.155800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.320400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.812800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.433400E-01 |
| Classical-VS-Follicular |
1.196750E-04 |
| Classical-VS-Other |
2.159600E-01 |
| Classical-VS-Normal |
9.650200E-01 |
| Tall-VS-Follicular |
7.149900E-02 |
| Tall-VS-Other |
3.300400E-01 |
| Tall-VS-Normal |
6.454200E-01 |
| Follicular-VS-Other |
9.482200E-01 |
| Follicular-VS-Normal |
6.757000E-03 |
| Other-VS-Normal |
1.837180E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.160100E-02 |
| Normal-vs-N1 |
6.582500E-02 |
| N0-vs-N1 |
6.422000E-01 |
|
|
